Clinicians weigh RCC immunotherapy choices by risk, metastasis site, and histology, citing durable outcomes with nivo-ipi and favoring TKIs after early progression.
|Videos|July 27, 2018
Upfront Therapy for mRCC
Kidney Cancer
Advertisement
Advertisement
Related to this article
FDA approves belzutifan plus lenvatinib for advanced clear cell RCC after PD-1/PD-L1 therapy, based on PFS and response rate benefit vs cabozantinib.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Denosumab Biosimilar Approved For Existing Oncology Indications
2
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
3
Giredestrant Plus Everolimus Improves PFS in ER+ Advanced Breast Cancer
4
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
5